National Health (Originator Brand) Amendment Determination 2017 (No. 1) (PB 11 of 2017) (Cth)

PB 11 of 2017

National Health (Originator Brand) Amendment Determination 2017 (No. 1)

National Health Act 1953

I, KAREN BINNEKAMP, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated        20   January 2017

______________________________________

KAREN BINNEKAMP

Assistant Secretary (Acting)

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2017 (No. 1).

(2)     This Determination may also be cited as PB 11 of 2017.

1. Commencement

This Determination commences on 1 February 2017.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1, (after table item 30)

Insert:

30A Calcipotriol with betamethasone Daivobet Daivobet 50/500 gel